MAO/EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE

MAO/非人类灵长类动物中艾滋病疫苗的评价

• 批准号: 2296404
• 负责人: RICHARD P BRADBURY
• 金额: $ 20.11万
• 依托单位: BIOQUAL, INC.
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-05-24 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/2296404
• 关键词: MAO; EVALUATION; AIDS; VACCINES; NON

The HIV Preclinical Vaccine Development Master Agreement Program was initiated to enable the NIAID to provide resources to accelerate the development of promising vaccine approaches. Under this program, a series of vaccine studies have been initiated to evaluate candidate and prototype AIDS vaccines in nonhuman primates. These studies are designed to obtain more information about the efficacy and optimum presentation of candidate HIV vaccines that are in human Phase l clinical trials or proposed for such trials as well as prototype SlV vaccines of the same type as these HIV vaccines. Other vaccine studies will evaluate prototype HIV or SIV vaccines that offer novel presentation systems, may be capable of eliciting broadly cross-reqactive immune responses, or have shown promising preliminary results. NIAID has initiated collaborative arrangements with researchers who have agreed to provide HIV and SlV vaccines for immunization of nonhuman primates. In all of the vaccine studies, the nonhuman primates will be challenged after immunization to determine if protection from infection or from disease can be obtained. The contractors in Category B of the Master Agreement Program, including the contractor listed above, will provide, house and care for, immunize, and challenge the nonhuman primates for the various vaccine studies. The contractors will obtain sera, cells, and other appropriate samples from the animals in the studies, and will ship the samples, as appropriate, to contractors for evaluation of humoral immune responses, including neutralizing antibodies, for evaluation of cellular immune responses, and for virological assessment after challenge. The category B contractors will maintain a data base for each study they are conducting in order to follow the immunization protocol, virus challenge, and all the assay results for each monkey in the study.

HIV临床前疫苗开发主协议计划 发起的目的是使 NIAID 能够提供资源来加速 开发有前景的疫苗方法。根据该计划，一系列 疫苗研究已启动以评估候选疫苗和原型 非人类灵长类动物的艾滋病疫苗。这些研究旨在获得 有关候选人的功效和最佳表现的更多信息 处于人类 I 期临床试验或拟用于的 HIV 疫苗 此类试验以及与这些相同类型的原型 SlV 疫苗 艾滋病毒疫苗。其他疫苗研究将评估 HIV 或 SIV 原型 提供新颖呈现系统的疫苗可能能够 引发广泛的交叉反应免疫反应，或已表明 有希望的初步结果。 NIAID 已发起合作 与同意提供 HIV 和 SlV 的研究人员进行安排 用于非人灵长类动物免疫的疫苗。在所有疫苗中 研究表明，非人类灵长类动物在免疫接种后将面临挑战 确定是否可以获得针对感染或疾病的保护。 主协议计划B类承包商，包括 上述承包商将提供住房和护理、免疫接种、 并挑战非人类灵长类动物进行各种疫苗研究。这 承包商将获得血清、细胞和其他适当的样本 研究中的动物，并将酌情将样本运送到 评估体液免疫反应的承包商，包括 中和抗体，用于评估细胞免疫反应，以及 用于攻击后的病毒学评估。 B类承包商 将为他们正在进行的每项研究维护一个数据库，以便 遵循免疫方案、病毒攻击和所有检测 研究中每只猴子的结果。